5/10
03:40 pm
mnpr
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Medium
Report
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.